Top-line phase 2a trial results of experimental psychedelic tryptamine showed a 57% reduction in major depressive disorder symptoms 3 months after a single dose when combined with supportive therapy.
Although guidelines caution against it, use of diphenhydramine in EDs more than doubled over a recent 11-year period, but recommended drugs such as triptans and corticosteroids were rarely prescribed.
Study results now extend evidence on the safety of of triptans for migraine in pregnancy and should reassure women who need to take this class of drugs while expecting.
For acute management of migraine, newer is not necessarily better, suggests a review and meta-analysis comparing triptans – the standard of care – to two newer classifications of medications.